Switch theme
Sign up to access all valuation multiples
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
2017
145
LTM Revenue $60.7M
LTM EBITDA $16.7M
$350M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Senores Pharmaceuticals has a last 12-month revenue (LTM) of $60.7M and a last 12-month EBITDA of $16.7M.
In the most recent fiscal year, Senores Pharmaceuticals achieved revenue of $46.1M and an EBITDA of $12.6M.
Senores Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Senores Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.7M | XXX | $46.1M | XXX | XXX | XXX |
| Gross Profit | $33.6M | XXX | $25.2M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $16.7M | XXX | $12.6M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $14.2M | XXX | $8.4M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $8.7M | XXX | $6.8M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $23.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Senores Pharmaceuticals's stock price is INR 697 (or $8).
Senores Pharmaceuticals has current market cap of INR 32.1B (or $372M), and EV of INR 30.2B (or $350M).
See Senores Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $350M | $372M | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Senores Pharmaceuticals has market cap of $372M and EV of $350M.
Senores Pharmaceuticals's trades at 8.6x EV/Revenue multiple, and 32.7x EV/EBITDA.
Equity research analysts estimate Senores Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Senores Pharmaceuticals has a P/E ratio of 42.5x.
See valuation multiples for Senores Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $372M | XXX | $372M | XXX | XXX | XXX |
| EV (current) | $350M | XXX | $350M | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | 21.0x | XXX | 32.7x | XXX | XXX | XXX |
| EV/EBIT | 24.6x | XXX | 48.4x | XXX | XXX | XXX |
| EV/Gross Profit | 10.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.5x | XXX | 62.0x | XXX | XXX | XXX |
| EV/FCF | -21.3x | XXX | -17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSenores Pharmaceuticals's last 12 month revenue growth is 57%
Senores Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Senores Pharmaceuticals's rule of 40 is 84% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Senores Pharmaceuticals's rule of X is 171% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Senores Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 78% | XXX | 78% | XXX | XXX | XXX |
| Rule of 40 | 84% | XXX | 84% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 171% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Senores Pharmaceuticals acquired XXX companies to date.
Last acquisition by Senores Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Senores Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Senores Pharmaceuticals founded? | Senores Pharmaceuticals was founded in 2017. |
| Where is Senores Pharmaceuticals headquartered? | Senores Pharmaceuticals is headquartered in India. |
| How many employees does Senores Pharmaceuticals have? | As of today, Senores Pharmaceuticals has 145 employees. |
| Is Senores Pharmaceuticals publicy listed? | Yes, Senores Pharmaceuticals is a public company listed on NSE. |
| What is the stock symbol of Senores Pharmaceuticals? | Senores Pharmaceuticals trades under SENORES ticker. |
| When did Senores Pharmaceuticals go public? | Senores Pharmaceuticals went public in 2024. |
| Who are competitors of Senores Pharmaceuticals? | Similar companies to Senores Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Senores Pharmaceuticals? | Senores Pharmaceuticals's current market cap is $372M |
| What is the current revenue of Senores Pharmaceuticals? | Senores Pharmaceuticals's last 12 months revenue is $60.7M. |
| What is the current revenue growth of Senores Pharmaceuticals? | Senores Pharmaceuticals revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Senores Pharmaceuticals? | Current revenue multiple of Senores Pharmaceuticals is 5.8x. |
| Is Senores Pharmaceuticals profitable? | Yes, Senores Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Senores Pharmaceuticals? | Senores Pharmaceuticals's last 12 months EBITDA is $16.7M. |
| What is Senores Pharmaceuticals's EBITDA margin? | Senores Pharmaceuticals's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Senores Pharmaceuticals? | Current EBITDA multiple of Senores Pharmaceuticals is 21.0x. |
| What is the current FCF of Senores Pharmaceuticals? | Senores Pharmaceuticals's last 12 months FCF is -$16.4M. |
| What is Senores Pharmaceuticals's FCF margin? | Senores Pharmaceuticals's last 12 months FCF margin is -27%. |
| What is the current EV/FCF multiple of Senores Pharmaceuticals? | Current FCF multiple of Senores Pharmaceuticals is -21.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
